Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib versus azathioprine for severe alopecia areata
IRCT20220904055876N1Phase 3Completed
- Sponsor
- Lady Reading Hospital
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of tofacitinib and azathioprine in alopecia areata, alopecia areata totalis (AT) and alopecia universalis (AU) (2 arms), sponsored by Lady Reading Hospital. Primary endpoints: Percent change in SALT score and Treatment efficacy threshold. Started Oct 2022; status: completed.
02
Drugs
tofacitinibazathioprine
03
Conditions
alopecia areataalopecia areata totalis (AT)alopecia universalis (AU)
Beyond the preview
Go deeper on IRCT20220904055876N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220904055876N1.